Back to results
US 10,479,838 B2Granted
Antibodies to CD40 with enhanced agonist activity
AssigneesBristol-Myers Squibb Company, The Rockefeller University
InventorsJeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
Life of this patent
Estimating the term…
Abstract
Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
Claims10
An isolated antibody or antigen binding portion thereof that specifically binds to human CD40 comprising:
- the CDRs of antibody 12D6-24 wherein CDRH 1, CDRH2 and CDRH3 comprise residues 31-35, 50-66 and 99-108, respectively, of SEQ ID NO:
- 12 and CDRL1, CDRL2 and CDRL3 comprise residues 24-39, 55-61 and 94-102, respectively, of SEQ ID NO:
- 9, wherein the antibody further comprises an Fc region modified to enhance specificity of binding to FcγRIIb, wherein the Fc region comprises a sequence selected from the group consisting of SE (SEQ ID NO:
- 66), SELF (SEQ ID NO:
- 67), P238D (SEQ ID NO:
- 68), V4 (SEQ ID NO:
- 69), V4 D270E (SEQ ID NO:
- 70), V7 (SEQ ID NO:
- 71), V8 (SEQ ID NO:
- 72), V9 (SEQ ID NO:
- 73), V9 D270E (SEQ ID NO:
- 74), V11 (SEQ ID NO:
- 75), and V12 (SEQ ID NO:
- 76).
11 more elements
Dependencies are inferred from the claim text.